

# Company Summary



## Investment Profile

1. Clearly defined path to commercialisation
2. "Fast-track" drug development strategy lowering developmental risk, costs and commercialisation timeframes
3. Good progress being made across all four of the Group's current drug development programmes, with lead drug candidate about to enter clinical trials
4. Extensive library of cannabinoid derivatives and patent families following exclusive Canopy Growth Corporation global licensing agreement
5. Highly qualified, industry-leading board
6. Best-in-class research and commercial partners

## Share Information

<b>Ticker(s)</b>	LSE: OCTP   OTCQB: OCTHF
<b>Share Price (GBX)</b>	0.78
<b>Shares in issue (m)</b>	960
<b>Market Cap (£m)</b>	7.4
<b>12m Hi/Low (GBX)</b>	2.5/0.4

## 12 - Month Share Price



(Source: The London Stock Exchange, February 2022)

## Major Shareholders (as of February 2023)

Name	% Holding
Kingsley Capital Partners LLP	20.76
Imperial Brands Ventures Limited	10.87
Kee Cheol Noh	5.29

(Source: Company Website - Percentages are undiluted)

## Company Overview

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of a pharmaceutical Group developing prescription cannabinoid medicines targeting the US\$ multi-billion global pain market.

OCTP currently has a portfolio of **four drug development programmes**. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with Phase 1 clinical trials, aimed at demonstrating safety and tolerability, due to commence in the near term. Interim trial results are expected in Q2 2023. **The global market for CIPN alone was valued at US\$1.61bn in 2020 and is forecast to reach US\$2.37bn by the year 2027.**

**OCTP's drug development pipeline, comprises both natural and synthetic compounds**, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation, comprising its entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of almost 500 derivatives and intellectual property rights including 14 patent families and associated research data.

**OCTP has a clearly defined path to commercialisation, revenues and growth.** The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

The agreements signed across all of the Group's drug programmes reflect **the Group's core ethos: to partner with organisations recognised as "best-in-class" that can drive quality and shareholder value.** In a cannabis market where unlicensed medicines remain abundant and unproven, the underlying philosophy remains unchanged: that it is only the development of cannabinoid-based medicines through the tried and tested channels of licensed drug development that allows the medical community to prescribe drugs with confidence and in volume.

OCTP has 'big pharma' capability

OCTP continues to expand its expertise and depth by engaging with globally recognised contract research organisations (CROs)

Programme 1 - OCT461201

Programme 2 - OCT18001

Programme 3 & 4



Added to this OCTP, as a pharmaceutical company, unlike a medical cannabis company, can chemically change its cannabinoid compounds to target specific conditions and ensure market exclusivity. OCTP intends to deliver medicines for conditions that remain unresolved or resistant to current treatments.

## What's New?

**The Company has successfully progressed all four drug development programmes, in line with the Company's strategic plan**, and have signed with several well-regarded organisations. To meet the Company's growth objectives, they listed on the US OTC QB market in December 2021.


On 4 January 2023 OCTP **submitted a combined clinical trials application for its lead programme, OCT461201**, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee. A review meeting was held on 11 January 2023 and the results are expected in the near term. Pre-clinical work on programmes 2,3 and 4 is ongoing.

The Company maintains a robust, debt-free balance sheet with cash reserves of approximately £5m at 31 October 2022.

## Strategy & Outlook

The Group continues to deliver successfully against its objective of bringing non-addictive cannabinoid-based licensed prescription medicines to patients who have been left behind by the opioid crisis. Development work and expenditure has progressed across all four current programmes. Following the reallocation of budgets announced in August 2022, the focus is now on the Company's drug candidate OCT461201, with Phase 1 clinical trials starting imminently.

The Board believes that the market has not yet fully recognised the true value of the Group. Despite the impact of worldwide economic and political influences impacting the whole sector, the Company is on a strong footing in 2023, and the Board remains confident in the long-term goal of revenue generation and growth in the multi-billion US\$ global pain market.




- **High potential pharmaceutical company developing next generation non-addictive pain medications to replace opioids**
- **Targeting the £59.5bn global pain market estimated to grow to £74.7bn by first launch**
- **Diversified pipeline with four drug development programmes. Phase I clinical trials on lead compound commencing imminently**
- **Targeting large and orphan indications with IP protection and market exclusivity**
- **Physicians can prescribe with confidence, insurers can reimburse**
- **The fundamentals of the Group remain strong, delivering against the strategy laid out in the IPO prospectus and with the Phase I clinical trial for Programme 1 fully funded.**



## Meet Oxford Cannabinoid Technologies

You can view the latest Company presentation and register to receive future presentations by signing up with **Investor Meet Company**. The Company also frequently appears on **Stockbox** and **Proactive** to discuss recent developments and answer frequently asked shareholder questions.

To view more information about OCTP, contact the Company, access the Company's social media, and sign up for RNS distributions, please scan the QR code here:



## Key Newsflow

### Jan- Half year Report

### Jan - Update on combined Clinical Trial Application

### Jan - Submission of combined Clinical Trial Application

### Dec - Trading Update

### Sep - Result of AGM

### Sep - Appointment of finnCap Ltd. as Corporate Broker

### Aug - Strategic Budget Review & Directorate Change

### Aug - Inaugural Meeting of Scientific Advisory Board

### Aug - Filing of 2022 Annual Report & Accounts

### Jul - 2022 Final Results

## Key Management

### Clarissa Sowemimo-Coker: Chief Executive Officer

Clarissa is a qualified solicitor and has nearly two decades of experience in the legal and regulatory sector. She joined the Group's executive team in December 2018 as General Counsel and Company Secretary. Prior to OCTP, she held senior roles at Google, Virgin Media and Hutchison 3G UK Limited. She was appointed to the Group's Board in February 2021 as Chief Operating Officer. Clarissa was instrumental in the Group's listing on the Main Market of the London Stock Exchange in May 2021. In December 2022 Clarissa was appointed as Chief Executive Officer on an interim basis, and is now responsible for the overall success of the Group.

### Paul Smalley: Finance Director

Prior to OCTP, Paul was with Panthera Biopartners Ltd, a clinical trials management company where he was the Finance Director and Company Secretary. CIMA qualified, with over 25 years' experience, he has extensive strategic management capabilities gained from various market sectors and has worked for organisations that range from SMEs to quoted companies. Paul holds a BA in Accounting and Finance from Lancaster.

### Julie Pomeroy: Non-Executive Chairman

Julie is an experienced finance director of quoted and private companies. She is a Chartered Accountant and Chartered Director. She also holds tax and treasury qualifications. Julie is a Non Executive Director at Dillistone Group Plc, an AIM quoted software business, where until September 2021 she was the group finance director and company secretary having joined in 2010. She was finance director of AIM quoted Biofutures International plc until July 2010 having joined in 2006.